John Wu

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Jayesh Desai, Sanjeev Deva, Jong Seok Lee et al. · Journal for ImmunoTherapy of Cancer · 2020 · 145 citations · Full text

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Michael Friedländer, Tarek Meniawy, Ben Markman et al. · The Lancet Oncology · 2019 · 113 citations

Medicine, Pharmacology, Advanced Solid Tumours +6

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

Zhenggang Ren, Michel Ducreux, Ghassan K. Abou‐Alfa et al. · Liver Cancer · 2022 · 71 citations · Full text

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedländer, Tarek Meniawy, Ben Markman et al. · Journal of Clinical Oncology · 2018 · 33 citations

Immunology, Immunoediting, Immunotherapeutics +17

Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID‐19 pandemic

John Gubatan, Thomas Zikos, Estelle Spear Bishop et al. · Neurogastroenterology & Motility · 2021 · 25 citations · Full text